Skip to content

Effect of a Daily Supplement on Plasma PAI-1 Levels

Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07469475
Enrollment
35
Registered
2026-03-13
Start date
2026-02-24
Completion date
2026-12-01
Last updated
2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Endothelial Dysfunction, Senescence

Keywords

Endothelial Dysfunction, Senescence

Brief summary

In a healthy person, the production of nitric oxide (NO) by the endothelium, the inner lining of the blood vessel, is responsible for a) the ability of the blood vessel to dilate so it can increase its blood flow and b) act as an anti-clotting product to prevent blood clotting in those vessels. Under physiological stress either due to the development of a disease such as diabetes or simply from aging, the endothelial cells can be impacted and become dysfunctional, thereby impairing their ability to make NO and even promoting the development of blood clots. When such endothelial dysfunction occurs, it may be a precursor for the future development of cardiovascular (CV) disease like hypertension or coronary artery disease later on in life in these patients. Therefore, the ability to enhance the local production or availability of NO within such affected blood vessels in patients identified as prone to endothelial dysfunction could play a positive role in either preventing or delaying the onset of endothelial dysfunction and subsequent CV disease in such patients. RM is an oral supplement consisting of natural ingredients and the amino acid, L-citrulline. In laboratory experiments with cells from the inner lining of blood vessels, the four components of RM have been shown to increase the concentration of NO and decrease the levels of some aging markers. In our recently completed study (manuscript currently in review), 31 young men and women took the supplement for 14 days and had no serious side effects. The supplement caused the expected potentially beneficial dilation of the blood vessels and decrease in the levels of Plasminogen Activator Inhibitor-1 (PAI-1), whose levels correlate with aging and risk of cardiovascular disease. In this study, healthy participants will consume the supplement for a 6-week period to determine if PAI-1 levels continue to be suppressed and also examine whether the supplement has an effect on other blood markers whose levels can change with aging or cardiovascular disease and may also be indicative or predictive of an illness.

Detailed description

This study examines the effect of six weeks of daily supplementation on a panel of blood markers associated with vascular aging and inflammation. The blood markers Plasminogen Activator Inhibitor-1 (PAI-1), Interleukin-8 (IL-8), Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), Fibroblast Growth Factor 23 (FGF-23), C-Reactive Protein (CRP), and Klotho will be measured. PAI-1 is a protein involved in blood clotting whose elevated levels are associated with increased cardiovascular risk and aging. IL-8 is a pro-inflammatory cytokine linked to chronic inflammation. PCSK9 is involved in lipid metabolism and cardiovascular risk. FGF-23 is a regulator of phosphate metabolism and vascular calcification. CRP is a general marker of system inflammation, and Klotho is an anti-aging protein with protective effects on vascular and renal function. By assessing these markers, this study seeks to determine whether a natural oral supplement can modulate key pathways involved in vascular inflammation and aging, potentially positioning it as a natural oral supplement that may support vascular health in the context of age-related decline.

Interventions

DIETARY_SUPPLEMENTSupplement with ginger extract, L-citrulline, Paullinia cupana, and muira puama

Participants will consume a supplement called RM, which is composed of ginger extract, L-citrulline, and the herbal components Paullinia cupana and muira puama.

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

35 healthy adult participants will be recruited. All participants will take the supplement twice daily for 6 weeks (42 days). Blood markers, blood pressure, and heart rate will be measured on day 0 and day 42.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* People of any gender at least 18 years of age who do not have a history of acute or chronic cardiovascular illnesses are eligible.

Exclusion criteria

* Younger than 18 years of age * Currently pregnant (which will be confirmed by pregnancy test for participants capable of pregnancy) * Using hormonal birth control * Current smoker * Allergy to ginger, muira puama, Paullinia cupana, or L-citrulline * Previous use of Revactin® or RM * History of serious cardiovascular events, including myocardial infarction (heart attack) or stroke * History of coronary, cardiac, or carotid surgery such as a stent, heart surgery, or endarterectomy * Active cancer of any type other than skin cancer

Design outcomes

Primary

MeasureTime frameDescription
Change in Blood Level of Plasminogen Activator Inhibitor-1 Between Baseline and 6 MonthsFrom enrollment to the end of treatment at 6 weeks +/- 7 daysBlood levels of Plasminogen Activator Inhibitor-1 (PAI-1), a marker that correlates with aging and risk of cardiovascular disease, will be measured through a standard blood draw. Measurement units are ng/mL.

Secondary

MeasureTime frameDescription
Change in Blood Level of Interleukin-8 Between Baseline and 6 MonthsFrom enrollment to the end of treatment at 6 weeks +/- 7 daysThe blood marker Interleukin-8 (IL-8) will be measured through a standard blood draw. IL-8 is a pro-inflammatory cytokine linked to chronic inflammation. Measurement units are pg/mL.
Change in Blood Level of Proprotein Convertase Subtilisin/Kexin Type 9 Between Baseline and 6 MonthsFrom enrollment to the end of treatment at 6 weeks +/- 7 daysThe blood marker Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) will be measured through a standard blood draw. PCSK9 is involved in lipid metabolism and cardiovascular risk. Measurement units are ng/mL.
Change in Blood Level of Fibroblast Growth Factor 23 (FGF-23) Between Baseline and 6 MonthsFrom enrollment to the end of treatment at 6 weeks +/- 7 daysThe blood marker Fibroblast Growth Factor 23 (FGF-23) will be measured through a standard blood draw. FGF-23 is a regulator of phosphate metabolism and vascular calcification. Measurement units are pg/mL.
Change in Blood Level of C-Reactive Protein Between Baseline and 6 MonthsFrom enrollment to the end of treatment at 6 weeks +/- 7 daysThe blood marker C-Reactive Protein (CRP) will be measured through a standard blood draw. CRP is a general marker of systemic inflammation. Measurement units are mg/dL.
Change in Blood Level of Klotho Between Baseline and 6 MonthsFrom enrollment to the end of treatment at 6 weeks +/- 7 daysThe blood marker Klotho will be measured through a standard blood draw. Klotho is an anti-aging protein with protective effects on vascular and renal function. Measurement units are pg/mL.
Change in Blood Pressure Between Baseline and 6 MonthsFrom enrollment to the end of treatment at 6 weeks +/- 7 daysSystolic and diastolic blood pressure will be measured. Measurement units are mm Hg.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSriram V Eleswarapu, MD, PhD

University of California, Los Angeles

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026